Elrexfio (elranatamab-bcmm) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has tried at least four systemic regimens
• Among the previous regimens tried, the patient has received at least one drug from each of the following classes: proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody
• Medication will be prescribed by or in consultation with an oncologist

Approval duration

1 year